ライフサイエンスコーパス: lymphadenopathy

1 pulmonary nodules, skeletal metastases, and lymphadenopathy).

2 d night sweats; imaging revealed generalized lymphadenopathy.

3 amination of bilateral hilar and mediastinal lymphadenopathy.

4 berculosis would be based primarily on hilar lymphadenopathy.

5 ce, although such rescue ultimately leads to lymphadenopathy.

6 in the lungs along with necrotic mediastinal lymphadenopathy.

7 ude autoimmune cytopenias, organomegaly, and lymphadenopathy.

8 control to provide nonmalignant inflammatory lymphadenopathy.

9 ms such as fever, maculopapular rash, and/or lymphadenopathy.

10 peripheral CD4(+) T cells and development of lymphadenopathy.

11 se with high-risk genomic features and bulky lymphadenopathy.

12 tent with the development of lymphopenia and lymphadenopathy.

13 ssessed for presence of pleural effusions or lymphadenopathy.

14 ion in the right parotid gland, and cervical lymphadenopathy.

15 eveloped an atypical phenotype with rash and lymphadenopathy.

16 iltrate, and CD62L correlated with extent of lymphadenopathy.

17 pendent antibody responses, splenomegaly and lymphadenopathy.

18 x-mediated nephritis and exhibit progressive lymphadenopathy.

19 with splenomegaly, hepatomegaly, and severe lymphadenopathy.

20 anges in the extremities, rash, and cervical lymphadenopathy.

21 be time dependent from the clinical onset of lymphadenopathy.

22 anted in order to determine the cause of the lymphadenopathy.

23 % reported weight loss, 40% fatigue, and 21% lymphadenopathy.

24 es of chemotherapy and to all sites of bulky lymphadenopathy.

25 characterised by fever, rash, headache, and lymphadenopathy.

26 performed in 247 patients with cervicofacial lymphadenopathy.

27 ion correlated with the presence of clinical lymphadenopathy.

28 ms of diarrhea, fatigue, localized rash, and lymphadenopathy.

29 phoma involving the liver and spleen without lymphadenopathy.

30 th incipient pneumonia, pleuritis, and hilar lymphadenopathy.

31 tases on pretherapy images, and 20 (65%) had lymphadenopathy.

32 nation revealed no palpable mass or axillary lymphadenopathy.

33 hography was also seen in acute inflammatory lymphadenopathy.

34 kable for bulky cervical and supraclavicular lymphadenopathy.

35 amination revealed also ipsilateral cervical lymphadenopathy.

36 stis spreads and thus leads to this striking lymphadenopathy.

37 h T1-2 primary breast cancer and no palpable lymphadenopathy.

38 fever, weight loss, hepatosplenomegaly, and lymphadenopathy.

39 of the left breast with no palpable axillary lymphadenopathy.

40 ls neither palpable breast mass nor axillary lymphadenopathy.

41 months later demonstrated enlarging cervical lymphadenopathy.

42 differentiate melanoma metastasis from other lymphadenopathies.

43 , constitutional symptoms (100%), peripheral lymphadenopathy (100%), splenomegaly (72%), hepatomegaly

44 Further, 16% had eschar, 29% had lymphadenopathy, 100% had gastrointestinal symptoms, 34%

45 ic Castleman's disease included multicentric lymphadenopathy (128/128), anaemia (79/91), elevated C-r

46 mass-like consolidation (20%), intrathoracic lymphadenopathy (16%), pleural effusion (12%), reticular

47 t, the patient developed non-tender cervical lymphadenopathy 2 days after a reduction in prednisone d

48 ry nodules (31.4%), mediastinal and/or hilar lymphadenopathy (23%), mass-like consolidation (17%), pl

49 ealed bilateral cervical and supraclavicular lymphadenopathy (6 x 5 cm with a standardized uptake val

50 ealed bilateral cervical and supraclavicular lymphadenopathy (6 x 5 cm).

51 with adverse characteristics including bulky lymphadenopathy (80%), extensive prior therapy (median 5

52 In patients with residual lymphadenopathy, a lack of abnormal 18F-FDG uptake in th

53 ia (CLL): a rapid and sustained reduction of lymphadenopathy accompanied by transient lymphocytosis,

54 No patient had lymphadenopathy, according to computerized tomographic o

55 ermed CD28-DeltaTreg mice), characterized by lymphadenopathy, accumulation of activated T cells, and

56 tumors presented clinically with generalized lymphadenopathy, advanced stage, and poor outcome (5-yea

57 tion allergies, in the incidence of fever or lymphadenopathy after vaccination, or in the dilution of

58 All patients presented with lymphadenopathy and 11% also had extranodal disease.

59 lance imaging identified new retroperitoneal lymphadenopathy and a large right pelvic mass with possi

60 rgan lymphocytic infiltration, but exhibited lymphadenopathy and accumulated large numbers of activat

61 -DeltaTreg mice prevented the development of lymphadenopathy and CD4(+) T cell activation, and autoim

62 l T cell manifestations persisted, including lymphadenopathy and cellular infiltrates of skin and liv

63 Conversely, lymphadenopathy and collapse had significant association

64 On the other hand, lymphadenopathy and collapse were closely associated wit

65 black woman diagnosed due to abdominal pain, lymphadenopathy and fever.

66 The etiology of the lymphadenopathy and follicular hyperplasia associated wi

67 years later, she presented with generalized lymphadenopathy and hepatosplenomegaly and a follicular

68 peaked 10 days postinfection, while minimal lymphadenopathy and higher glycolytic activity were obse

69 Lymphadenopathy and immune activation in the axillary ly

70 he skin and lungs, accompanied by peripheral lymphadenopathy and increased differentiation of skin-tr

71 ntrols, PD-L1/2(-/-)LDLR(-/-) mice had iliac lymphadenopathy and increased numbers of activated CD4(+

72 Cervical lymphadenopathy and initial bed rest were associated wit

73 hological studies revealed moderate cervical lymphadenopathy and lymphoplasmacytic infiltrate, but th

74 etains more cells at these sites, leading to lymphadenopathy and massive bystander activation that ch

75 abdomen, and pelvis was requested to depict lymphadenopathy and organomegaly.

76 stology was predominantly angioimmunoblastic lymphadenopathy and PTCL not otherwise specified.

77 The disease presented as localized lymphadenopathy and showed a favorable response to chemo

78 Reductions in lymphadenopathy and splenomegaly are seen within weeks a

79 LPS) presents in childhood with nonmalignant lymphadenopathy and splenomegaly associated with a chara

80 ule (TRAF2DN), which mimics TRAF1, developed lymphadenopathy and splenomegaly due to polyclonal B cel

81 showed an absence of autoantibodies, reduced lymphadenopathy and splenomegaly, and extended survival.

82 nt female MRL/lpr mice developed exacerbated lymphadenopathy and splenomegaly, higher serum anti-chro

83 e in peripheral B cells, which culminates in lymphadenopathy and splenomegaly, hypergammaglobulinemia

84 Lymphadenopathy and splenomegaly, which are characterist

85 n addition, these animals displayed systemic lymphadenopathy and splenomegaly.

86 e, disappearance of fever, and regression of lymphadenopathy and splenomegaly.

87 Most patients presented with lymphadenopathy and splenomegaly; fever, hepatitis, and

88 tic monoclonal antibody to CD137 (2A) blocks lymphadenopathy and spontaneous autoimmune diseases in F

89 e shown that Sle2c1 increases lpr-associated lymphadenopathy and T cell-mediated pathology.

90 to a limited degree, the ability to suppress lymphadenopathy and T helper cell type 2 activation.

91 ed in the differential diagnosis of inguinal lymphadenopathy and the diagnosis is possible with cytop

92 pancies were seen most commonly in detecting lymphadenopathy and visceral metastases.

93 tive lymphocyte apoptosis results in chronic lymphadenopathy and/or splenomegaly associated with auto

94 th acute febrile illness, systemic symptoms, lymphadenopathies, and/or multiorgan failure to rapidly

95 e, 1 had miliary tuberculosis (TB), 2 had TB lymphadenopathy, and 1 had active pulmonary TB.

96 ickening involving the base of the appendix, lymphadenopathy, and appendiceal diameter.

97 th CCL21 and CCL19, correlated with clinical lymphadenopathy, and blocking of CCR7 inhibited CLL cell

98 e and size of pleural effusions and ascites, lymphadenopathy, and distant metastases.

99 ntibodies, exhibited marked splenomegaly and lymphadenopathy, and elevated serum IL-6.

100 high fever, rash, mucositis, conjunctivitis, lymphadenopathy, and extremity changes are superficially

101 ous liver enhancement, biliary duct changes, lymphadenopathy, and findings of portal hypertension.

102 ese episodes included bowel wall thickening, lymphadenopathy, and focal masses.

103 e significantly more likely to have fatigue, lymphadenopathy, and headache, as well as a longer durat

104 h P/EP CMV, symptoms including splenomegaly, lymphadenopathy, and hepatomegaly were associated with n

105 Fever, lymphadenopathy, and hepatosplenomegaly were often obser

106 pical signs of MAIDS including splenomegaly, lymphadenopathy, and hypergammaglobulinemia.

107 transitional B cells and senescent T cells, lymphadenopathy, and immune deficiency (activated PI3Kde

108 inal lymphangiectasia, mesenteric lymph node lymphadenopathy, and lymphangiogenesis in both the mesen

109 time, they developed severe splenomegaly and lymphadenopathy, and most animals also developed leukemi

110 Four infants had rash, lymphadenopathy, and oligoclonal populations of T cells

111 e responses to mitogens or who develop rash, lymphadenopathy, and oligoclonal T cells.

112 Hepatitis, lymphadenopathy, and other inflammatory sequelae are adv

113 RM, inducing B cell hyperplasia, persistent lymphadenopathy, and persistent infection in these anima

114 cterized by fever, tachycardia, hypotension, lymphadenopathy, and pruritus.

115 the most common adverse events being fever, lymphadenopathy, and rash.

116 and lacrimal and salivary glands pathology, lymphadenopathy, and splenomegaly are dramatically suppr

117 ing rapid improvement in autoimmune disease, lymphadenopathy, and splenomegaly within 1 to 3 months o

118 (skin, salivary and lacrimal glands, lungs, lymphadenopathy, and splenomegaly) is equivalent in ICOS

119 ncluding reductions in leukemia cell counts, lymphadenopathy, and splenomegaly.

120 ealed progressive pelvic and retroperitoneal lymphadenopathy, and the patient enrolled in a clinical

121 Transgenic mice showed lymphadenopathy, and transgenic T cells displayed increa

122 der characterized by chronic fatigue, fever, lymphadenopathy, and/or hepatosplenomegaly, associated w

123 The determinants of HIV-1-associated lymphadenopathy are poorly understood.

124 mmon lesions of the adrenal gland and showed lymphadenopathy around the major vessels of the abdomen.

125 Stat3 CKO mice developed cervical lymphadenopathy as well as a mild ileocolitis that persi

126 creased serum immunoglobulin G2a levels, and lymphadenopathy associated with increased gamma interfer

127 senteric involvement, and supradiaphragmatic lymphadenopathy at CT were associated with BRCA mutation

128 observed only in patients who had developed lymphadenopathy at least 4 months earlier.

129 of marginal zone macrophages, splenomegaly, lymphadenopathy, autoantibodies (including anti-DNA IgG)

130 lopment of significant autoimmune-associated lymphadenopathy, autoantibodies, and renal disease.

131 Here we show that, in patients with lymphadenopathy, autocrine VEGF and alpha(4)beta(1) inte

132 riety of clinical features, with most having lymphadenopathy, autoimmune cytopenias, multiorgan autoi

133 optotic functions of RIPK3 contribute to the lymphadenopathy, autoimmunity, and excess cytokine produ

134 s macaques developed fever, classic eschars, lymphadenopathy, bacteremia, altered liver function, inc

135 udarabine-refractory CLL with bulky (> 5 cm) lymphadenopathy (BF-ref) who are less suitable for alemt

136 aemia requiring treatment who had measurable lymphadenopathy by CT or MRI and disease progression wit

137 These mice seem immunocompetent but develop lymphadenopathy by four months of age marked by accumula

138 IgG1 and IgG2a, and reduced skin lesions and lymphadenopathy, compared with control mice.

139 The negative smear group featured lymphadenopathy, consolidation, collapse and nodular inf

140 transplantation included eosinophilia, rash, lymphadenopathy, development of CD4-CD8- peripheral T ce

141 imals had a delayed onset of the FIV-induced lymphadenopathy, did not develop or had a significant de

142 -/-) mice manifested severe splenomegaly and lymphadenopathy, dramatically increased proinflammatory

143 th increased distal ileum wall thickness and lymphadenopathy during the illness period.

144 ult in an individual who has recent onset of lymphadenopathy (e.g., within 2 to 3 months of sera samp

145 patients had rash or eschar, eight (29%) had lymphadenopathy, eight (29%) had gastrointestinal sympto

146 f B-cell hyperactivity such as splenomegaly, lymphadenopathy, elevated serum IL-6, elevated serum aut

147 lesion, Castleman disease, organomegaly (or lymphadenopathy), endocrinopathy, edema (peripheral edem

148 ifestations were noted: fever, sialadenitis, lymphadenopathy, erythema nodosum, leukocytoclastic vasc

149 usions, linear opacities, septal thickening, lymphadenopathy, extent of parenchymal involvement, and

150 functional FasL expression on T cells but no lymphadenopathy, fail to develop IDDM.

151 the formation of satellite lesions, regional lymphadenopathy, fever, headache, nausea, muscle aches,

152 epatosplenomegaly, often without significant lymphadenopathy, fever, liver failure, pancytopenia, and

153 aglobulinemia, resulting in splenomegaly and lymphadenopathy, followed many weeks later by death.

154 were observed in patients who had developed lymphadenopathy from <1 month to 17 months prior to the

155 tation of the Fas death receptor, is massive lymphadenopathy from aberrant expansion of CD4(-)CD8(-)

156 d by hypergammaglobulinemia, autoantibodies, lymphadenopathy, glomerulonephritis, and vasculitis.

157 toimmune disease manifested by splenomegaly, lymphadenopathy, glomerulonephritis, elevated autoantibo

158 Lymphadenopathy > or = 5 cm, but not cytogenetic abnorma

159 These included splenomegaly, lymphadenopathy, hepatomegaly, multifocal hepatitis, ane

160 Rare cases are disseminated with lymphadenopathy, hepatosplenomegaly, and a leukemic phas

161 defective Fas-mediated apoptosis, leading to lymphadenopathy, hepatosplenomegaly, and an increased nu

162 ifest in childhood with chronic nonmalignant lymphadenopathy, hepatosplenomegaly, and recurring multi

163 ALPS) is characterized by childhood onset of lymphadenopathy, hepatosplenomegaly, autoimmune cytopeni

164 d hyperattenuation on arterial phase images, lymphadenopathy, heterogeneity, extrahepatic metastases,

165 -infected C57BL/6 mice develop splenomegaly, lymphadenopathy, hypergammaglobulinemia, and immunodefic

166 type MCD, including splenomegaly, multifocal lymphadenopathy, hypergammaglobulinemia, and plasmacytos

167 retroviruses develop profound splenomegaly, lymphadenopathy, hypergammaglobulinemia, terminal B-cell

168 Patients with isolated mediastinal lymphadenopathy (IML) are a common presentation to physi

169 tiation resulted in reduced splenomegaly and lymphadenopathy, impaired expansion and activation of T

170 ), a central scar in 22 (71%), and abdominal lymphadenopathy in 20 (65%).

171 ns elicited productive viral replication and lymphadenopathy in a dose-dependent fashion.

172 Lymphadenopathy in autoimmune and other lymphoproliferat

173 cells, and showed reduced autoreactivity and lymphadenopathy in C57BL/6/lpr, and reduced mortality in

174 Lymphadenopathy in children for which no infectious or m

175 icular lymphoma (FL) presenting as localized lymphadenopathy in children.

176 ut not involuted follicles of HIV-associated lymphadenopathy in eight cases, supporting the notion th

177 intrahepatic bile ducts in 17, and abdominal lymphadenopathy in eight.

178 as well as retrocrural and internal mammary lymphadenopathy in Hodgkin's lymphoma than in sarcoidosi

179 Tumor-reactive lymphadenopathy in SLNs has been observed for decades, b

180 e development of splenomegaly accompanied by lymphadenopathy in some mice.

181 19), mesenteric involvement (OR = 7.10), and lymphadenopathy in supradiaphragmatic (OR = 2.83) and su

182 used by an undiagnosed primary melanoma with lymphadenopathy in the groin, one patient withdrew becau

183 nitrite use (OR, 7.0; 95% CI, 2.1-23.0), and lymphadenopathy in the past 6 months (OR, 7.7; 95% CI, 1

184 ished disease results in rapid regression of lymphadenopathy, in part because of apoptosis of the mal

185 veral hallmarks of SUDV infection, including lymphadenopathy, increased liver enzyme activities, and

186 arkedly delayed the onset of proteinuria and lymphadenopathy, increased survival, and reduced levels

187 Despite the lack of measurable lymphadenopathy, infection was associated with an increa

188 tor autoantibodies, total serum Ig isotypes, lymphadenopathy, inflammatory infiltrates in the salivar

189 d core biopsy in patients with head and neck lymphadenopathy is a safe outpatient procedure that has

190 c ultrasound is useful in staging NSCLC when lymphadenopathy is present on a computed tomography (CT)

191 risk-stratification model, patients who had lymphadenopathy less than 5 cm and no comorbidities had

192 BALB/c mice also developed lymphadenopathy, liver dysfunction, and decreased NK cel

193 Lymphadenopathy (LN) is the most common clinical manifes

194 ates, no cough, and tender anterior cervical lymphadenopathy (lymphadenitis).

195 Ag-induced peripheral T cell deletion, their lymphadenopathy may result from unrestrained homeostatic

196 y in inguinal and internal iliac nodes, with lymphadenopathy measuring up to 3.5 cm.

197 was associated with hypermetabolic symmetric lymphadenopathy (median maximal standardized uptake valu

198 ) animals aged, they developed splenomegaly, lymphadenopathy, membranoproliferative glomerulonephriti

199 EUS detected malignant mediastinal lymphadenopathy more frequently in patients with lower l

200 arlier appearance of skin lesions, increased lymphadenopathy, more severe glomerulonephritis, and hig

201 t Rabgef1-/- mice also develop splenomegaly, lymphadenopathy, myeloid hyperplasia, and high levels of

202 ations included fungemia (n = 2), multifocal lymphadenopathy (n = 2), and necrotizing pneumonia (n =

203 Masses (n = 2), lymphadenopathy (n = 2), areas of consolidation (n = 2),

204 l bascule (n=1), ileus (n=1), and metastatic lymphadenopathy (n=1).

205 ia (n=9), fibrofatty proliferation (n=8) and lymphadenopathy (n=28).

206 In patients without residual lymphadenopathy, neck dissection may be withheld safely.

207 tis, hepatitis, pancreatitis, iridocyclitis, lymphadenopathy, neuropathies, and nephritis have also b

208 nts presented with sinopulmonary infections, lymphadenopathy, nodular lymphoid hyperplasia and viremi

209 Chest CT scans revealed lymphadenopathy, nodules, thickened interlobular septa,

210 ntly increased local immune infiltration and lymphadenopathy of the draining lymph node.

211 in unprotected animals was rapid and severe lymphadenopathy of the mediastinal lymph node cluster, w

212 Women with evidence of lymphadenopathy on computed tomographic scanning or lymp

213 terlobular septal thickening and mediastinal lymphadenopathy on computed tomography of the chest comp

214 Lack of residual lymphadenopathy on CT had an NPV of 96%.

215 ography (CT), but its role in the absence of lymphadenopathy on CT has not been well defined.

216 ients with NSCLC with absence of mediastinal lymphadenopathy on CT were enrolled and followed prospec

217 ) in staging NSCLC in absence of mediastinal lymphadenopathy on CT.

218 The presence of lymphadenopathy on physical examination was the most use

219 ly subclinical but in some patients cervical lymphadenopathy or ocular disease can be present.

220 ), weight loss of >10% (OR, 10.0; P = .001), lymphadenopathy (OR 6.8; P = .002), HIV infection (OR, u

221 ia, constitutional symptoms, hyperviscosity, lymphadenopathy, or hepatosplenomegaly).

222 ndritic cells and did not have splenomegaly, lymphadenopathy, or inflammation in multiple organs.

223 nodules, vascular encasement, peripancreatic lymphadenopathy, or metastases.

224 iomata, particularly with systemic symptoms, lymphadenopathy, or other benign vascular endothelial gr

225 -cell lymphoproliferative disorder including lymphadenopathy/organomegaly.

226 elanoma lymph node metastases from the other lymphadenopathies (P < .05 for both) in vivo, whereas FD

227 per quadrant (P = .0003), supradiaphragmatic lymphadenopathy (P = .0004), more peritoneal disease sit

228 d by a CD4cre transgene led to age-dependent lymphadenopathy partly because of abnormal expansion of

229 pr animals showed a significant reduction in lymphadenopathy, pathogenic autoantibodies, and end-orga

230 Even in the absence of a mass lesion or lymphadenopathy, peripheral T cell lymphoma should be in

231 In contrast to residual lymphadenopathy, persisting splenomegaly does not impact

232 rter, mutations in which cause histiocytosis-lymphadenopathy plus syndrome, a group of conditions wit

233 mice develop a lupus-like disease as well as lymphadenopathy, polyclonal lymphocyte activation, and a

234 ociated lymphoid tissue (NALT) plus cervical lymphadenopathy prior to bacteremic dissemination.

235 for evaluation of rapidly enlarging cervical lymphadenopathy, progressive dyspnea, fatigue, night swe

236 Chest radiographs revealed lymphadenopathy, pulmonary nodules, focal consolidation,

237 graphic (CT) scans (n = 8) were assessed for lymphadenopathy, pulmonary nodules, focal consolidation,

238 flammatory condition characterized by fever, lymphadenopathy, rash, arthritis, and serositis.

239 Simvastatin also reduced the lymphadenopathy, renal disease, and proinflammatory cyto

240 lopment of B-cell hyperplasia and persistent lymphadenopathy resembling multicentric Castleman diseas

241 tations; all but 1 patient had a decrease in lymphadenopathy, resulting in 1 IWCLL partial response (

242 even patients; 29%), > or = 50% reduction of lymphadenopathy (seven of 22 patients; 32%), and > or =

243 cytosis and sinus histiocytosis with massive lymphadenopathy (SHML), characterized by severe tissue i

244 d enhancement of the septum, and mediastinal lymphadenopathy should raise the suspicion for CS.

245 , whereas patients with MRD-negative PR with lymphadenopathy showed a shorter PFS (31 months; P < .00

246 had an LR of 0.5 or less, but the absence of lymphadenopathy slightly decreased the likelihood of ear

247 acterized by defective lymphocyte apoptosis, lymphadenopathy, splenomegaly and autoimmunity.

248 statistically significant decrease in DNTs, lymphadenopathy, splenomegaly, and autoantibodies after

249 d.apoE(-/-) mice also displayed increases in lymphadenopathy, splenomegaly, and autoantibodies compar

250 Clinical manifestations include lymphadenopathy, splenomegaly, and autoimmune cytopenias

251 described a syndrome of chronic nonmalignant lymphadenopathy, splenomegaly, and autoimmunity associat

252 While Fas-deficient mice display marked lymphadenopathy, splenomegaly, and lymphocytosis, TDAG51

253 ipients resulted in T and B cell activation, lymphadenopathy, splenomegaly, and the production of IgG

254 lta) in a patient who presented with chronic lymphadenopathy, splenomegaly, autoantibodies, elevated

255 Results from this study reveal significant lymphadenopathy, splenomegaly, elevated titers of anti-n

256 drome (ALPS) is characterized by early-onset lymphadenopathy, splenomegaly, immune cytopenias, and an

257 n of lymphocytes and childhood onset chronic lymphadenopathy, splenomegaly, multilineage cytopenias,

258 We found no significant difference in lymphadenopathy, splenomegaly, or anti-chromatin autoant

259 ighly elevated and 33% of patients exhibited lymphadenopathy, suggesting frequently the diagnosis of

260 nucleosis is reduced with the absence of any lymphadenopathy (summary sensitivity, 0.91; positive LR

261 ble and fertile but rapidly developed severe lymphadenopathy, systemic autoimmune disease, and thromb

262 B6.p18(-/-).lpr mice showed a greater lymphadenopathy than B6.Sle2c1.lpr mice, but their renal

263 uble deficiency of Bim and Bmf caused more B lymphadenopathy than loss of either BH3-only protein alo

264 tal role respectively in epidermotropism and lymphadenopathy that is observed in SS.

265 with lpr, resulting in a greatly accelerated lymphadenopathy that largely targeted T cells and mapped

266 nantly young males presenting with localized lymphadenopathy; the tumor shows high-grade cytology and

267 ic phenotype, characterized by splenomegaly, lymphadenopathy, thymic atrophy, and multiple abnormalit

268 Toxoplasmic lymphadenopathy (TL) is the most common clinical manifes

269 77 patients (6.5%), while hilar/mediastinal lymphadenopathy was found in 25 of 76 patients (33%).

270 easured up to 5 mm, and no additional pelvic lymphadenopathy was identified.

271 At presentation, generalized lymphadenopathy was noted in 76% of patients, and 89% ha

272 Lymphadenopathy was observed in 12% of patients.

273 Neither fever nor lymphadenopathy was observed.

274 ts, endoscopic US-guided FNAB of mediastinal lymphadenopathy was performed as a component of staging

275 Lymphadenopathy was seen in 1 case with gallbladder carc

276 Lymphadenopathy was seen in 47 (88%) patients.

277 ung, lacrimal and salivary glands, skin, and lymphadenopathy) was diminished.

278 psy in differentiating benign from malignant lymphadenopathy were 98.1%, 100%, and 98.7%, respectivel

279 cy in differentiating lymphoma from reactive lymphadenopathy were 98.5%, 100%, and 98.7%, respectivel

280 f biliary dilatation, vascular invasion, and lymphadenopathy were assessed.

281 h T1-2 primary breast cancer and no palpable lymphadenopathy were enrolled in the randomised, multice

282 In this study, 132 patients with lymphadenopathy were investigated.

283 d enhancement of the septum, and mediastinal lymphadenopathy were more often see in those with CS (P<

284 s, reticular opacities, pleural effusion, or lymphadenopathy were not observed in any patient.

285 al border cortical destruction, and cervical lymphadenopathy were noted more frequently in the recurr

286 Declines in ALC and/or lymphadenopathy were observed in the majority of patient

287 f mice, the involvement of NALT and cervical lymphadenopathy were observed, indicating entry via both

288 Patients with cervical lymphadenopathy were prospectively enrolled between Apri

289 nically </= 4 cm in diameter and no axillary lymphadenopathy were prospectively entered onto a trial

290 , and lymph-node aspirate (for patients with lymphadenopathy) were obtained for mycobacterial culture

291 ctively reduced the number of DN T cells and lymphadenopathy, whereas selective expansion of Treg by

292 ty-six consecutive patients with mediastinal lymphadenopathy who did not have a primary gastrointesti

293 in 12 consecutive patients with mediastinal lymphadenopathy who had previously undergone nondiagnost

294 uman immunodeficiency virus (HIV)-associated lymphadenopathy with a Castleman's disease-like appearan

295 istration resulted in overt splenomegaly and lymphadenopathy with a significant increase in the numbe

296 mice developed progressive splenomegaly and lymphadenopathy with accumulation of engorged macrophage

297 phoma showed splenomegaly, hepatomegaly, and lymphadenopathy with involvement of bone marrow, thymus,

298 significant reduction or a mixed response in lymphadenopathy without concomitant development of B-cel

299 onfirmed the lung lesion and the mediastinal lymphadenopathy without distant metastases.

300 Low attenuation mesenteric lymphadenopathy, without enlarged small bowel segments w